secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2022-10-12T23:59:59+00:00
Accession:  0001213900-22-063416
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401
--------------------------------------------------------------------------------

- Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.
- CIP-137401 is a macrocyclic MEK inhibitor for NF1 and Noonan syndrome; already has FDA orphan-drug designation for NF1.
- Plans to file IND in 2H 2023 and initiate Phase 1 trial in NF1; expects synergies with existing MS program.
- Daniel Schneiderman appointed CFO effective Oct 11, 2022 with base salary $330K and 300K stock options.
- Sellers subject to two-year lock-up; 1.35M shares lock up release at one year, then 112.5K monthly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/0001213900-22-063416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/ea167014-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-063416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer